Android app on Google Play

Optimer Pharma (OPTR) Will Get Milestone Payments from Specialised Therapeutics Australia for Fidaxomicin

June 19, 2012 8:58 AM EDT Send to a Friend
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Specialised Therapeutics Australia Pty, Ltd. (STA) announced today the execution of an exclusive agreement to register and commercialize fidaxomicin tablets in Australia and New Zealand for the treatment of Clostridium difficile Infection (CDI).

Under the agreement Optimer is entitled to receive commercial milestone payments upon the achievement of cumulative net sales targets. In addition, Optimer will also receive payments for the supply of fidaxomicin tablets to STA for a return equivalent to approximately 30% of expected fidaxomicin sales in Australia and New Zealand. STA is responsible for all costs associated with the registration and commercialization of fidaxomicin tablets in Australia and New Zealand.




You May Also Be Interested In


Related Categories

Corporate News

Add Your Comment